Hcw biologics poster presentation at aacr annual meeting 2023

Presentation of data for the mechanism underlying hcw9218 against solid tumors hcw9218 is the clinical-stage, lead product candidate of hcw biologics inc. miramar, fla., april 13, 2023 (globe newswire) -- hcw biologics inc. (the “company” or “hcw biologics”) (nasdaq: hcwb), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that data for the mechanism underlying hcw9218 against solid tumors will be presented at the 2023 annual meeting of the american association for cancer research to be held in orlando, florida from april 14 – april 19, 2023.
HCWB Ratings Summary
HCWB Quant Ranking